Abstract: The present invention provides novel polynucleotides encoding MMP-29 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MMP-29 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Abstract: Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.
Type:
Grant
Filed:
June 20, 2001
Date of Patent:
November 1, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, Marco M. Gottardis, Ricardo M. Attar, Stanley R. Krystek, Jr., John S. Sack
Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
September 13, 2005
Assignee:
Coley Pharmaceuticals GmbH
Inventors:
Stefan Bauer, Grayson Lipford, Hermann Wagner
Abstract: The present invention is broadly directed to methods of screening ribosomal protein L11/GTPase activating region (GAR) RNA-modulating compounds by using information from the high-resolution structure of the L11/GAR complex. The methods are useful in identifying compounds useful for anti-bacterial treatments.
Type:
Grant
Filed:
November 1, 2001
Date of Patent:
January 18, 2005
Assignee:
University of Utah Research Foundation
Inventors:
Brian T. Wimberly, Venkatraman Ramakrishnan
Abstract: The present invention relates to nucleic acid sequences from the bacterium, Myxococcus xanthus and, in particular, to genomic DNA sequences. The invention encompasses nucleic acid molecules present in non-coding regions as well as nucleic acid molecules that encode proteins and fragments of proteins. In addition, proteins and fragments of proteins so encoded and antibodies capable of binding the proteins are encompassed by the present invention. The invention also encompasses oligonucleotides including primers, e.g. useful for amplifying nucleic acid molecules, and collections of nucleic acid molecules and oligonucleotides, e.g. in microarrays. The invention also provides constructs and transgenic cells and organisms comprising nucleic acid molecules of the invention.
Type:
Grant
Filed:
July 10, 2001
Date of Patent:
December 21, 2004
Assignee:
Monsanto Technology, LLC
Inventors:
Barry S. Goldman, Gregory J. Hinkle, Steven C. Slater, Roger C. Wiegand
Abstract: A method comprises (A) defining a first experimental space comprising factors of at least two mixtures with at least one common factor, (B) defining a second experimental space by deleting duplicate factor combinations from the first experimental space and (C) conducting an experiment on the second experimental space. A system comprises a processor that (A) defines a first experimental space comprising factors of at least two mixtures with at least one common factor and (B) defines a second experimental space by deleting duplicate factor combinations from the first experimental space. The system also comprises a reactor and evaluator to select a best case set of factors from the second experimental space by a combinatorial high throughput screening (CHTS) method to select a best case set of factors from the second experimental space.
Type:
Grant
Filed:
October 25, 2000
Date of Patent:
November 30, 2004
Assignee:
General Electric Company
Inventors:
James Norman Cawse, Ronald James Wroczynski, Darchun Billy Yang
Abstract: The present invention provides to polynucleotides and secreted proteins encoded by the polynucleotides. The proteins include a variety of fusion proteins, including fusions comprising a signal peptide selected from the group consisting of signal peptides shown in SEQ ID NO:M, wherein M is an even integer from 2 to 328, operably linked to a second polypeptide. The invention further provides therapeutic and diagnostic methods utilizing the polynucleotides, polypeptides, and antagonists of the polypeptides.
Abstract: An automated modeler for modeling of an interactive system comprising at least one biological entity and at least one pharmaceutical substance, the system comprising, a representation of states of said system, a knowledge tree builder, associated with said representation for allowing users to define the states, expected relationships between said states and independent inputs to the states, and a data miner associated with said representation to operate on data taken from said system to apply said data to said states in accordance with said defined relationships and inputs, thereby to apply numerical values to said relationships and said inputs, thereby to model said interactions.
Abstract: The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in human C3A liver cell cultures treated with steroids or synthetic steroid analogues and which may be used entirely or in part to detect metabolic and toxicological responses to treatment with steroids and steroid antagonists, to diagnose, to stage, to treat, or to monitor the treatment of a subject with an steroid responsive disorder.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
January 6, 2004
Assignee:
Incyte Corporation
Inventors:
L. Michael Furness, Jenny L. Buchbinder
Abstract: The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.
Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations.
Type:
Grant
Filed:
November 27, 2000
Date of Patent:
December 30, 2003
Assignee:
Cellomics, Inc.
Inventors:
R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano